ReviewExpert review of clinical immunology2017
PD-1/PD-L1 blockade in renal cell cancer.
Review in Expert review of clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review.World journal of urology · 2026Pooled it
- First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.Oncology and therapy · 2026Review
- Article
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.Antibody therapeutics · 2025Article
- Review
- Transcutaneous Imiquimod Combined With Anti-Programmed Cell Death-1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma.Cancer medicine · 2025Article
- Flavonoids as modulators of metabolic reprogramming in renal cell carcinoma (Review).Oncology reports · 2024Review
- Article
- CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.Molecular therapy oncolytics · 2021Article
- Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases.Frontiers in genetics · 2021Review
- A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.Frontiers in immunology · 2021Article
- CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.JCI insight · 2020Article
- Article
- Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.BMC cancer · 2019Article
- A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.Current urology reports · 2019Review
- Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma.Cancer immunology, immunotherapy : CII · 2018Article
- Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.Wiener klinische Wochenschrift · 2018Review
- A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionImmunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.